中文摘要：

目的研究供受者ABO血型不合对单份非血缘脐血造血干细胞移植（ucBT）患者中性粒细胞、血小板、红细胞植入，急性移植物抗宿主病（aGVHD）累积发生率及180d移植相关死亡率（TRM）的影响。方法以2008年4月至2014年10月行单份UCBT的208例患者为研究对象，其中供受者ABO血型相合99例，次要不合60例，主要不合38例，主次均不合11例。全部患者均采用强化清髓预处理方案，并予环孢素联合霉酚酸酯方案预防GVHD。结果ABO血型相合与不合的UCBT相比，中性粒细胞、血小板、红细胞累积植入率，Ⅱ-Ⅳ度aGVHD、Ⅲ-Ⅳ度aGVHD及180dTRM的累积发生率差异均无统计学意义（尸值均〉0．05），且无一例发生纯红细胞再生障碍。A供0血型不合患者中性粒细胞、血小板、红细胞的中位植入时间分别为＋17（＋12～＋28）、＋37（＋17～＋57）、＋25（＋13～＋52）d，Ⅱ～Ⅳ度aGVHD、Ⅲ～Ⅳ度aGVHD及180dTRM累积发生率分别为37．50％（95％C134．39％-40．61％）、6．25％（95％CI5．48％-7．02％）及23．53％（95％CI21．30％～25．76％）。与ABO血型相合、次要不合及主次均不合组比较，差异均无统计学意义（P值均〉0．05）。结论接受ABO血型不合UCBT的患者移植后无纯红细胞再生障碍发生。供受者ABO血型不合对UCBT患者的造血重建、aGVHD发生率及TRM均无影响。

英文摘要：

Objective To retrospectively study the impacts of ABO incompatibility on early outcome after single unit unrelated cord blood transplantation （UCBT）, such as cumulative incidence of engraftment, incidence of acute graft- versushost disease （aGVHD） and 180- day transplantrelated mortality （TRM）. Methods 208 patients underwent single unit UCBT from April 2008 to October 2014 were analyzed, included 99 ABO-identical, 60 minor, 38 major and 11 bidirectional ABO-incompatible recipients. All the patients received intensified myeloablative conditioning, and a combination of cyclosporine A and mycophenolate mofetil was given for GVHD prophylaxis. Results Cumulative incidences of neutrophil engraftment, platelet recovery, erythroid lineage reconstitution, Ⅱ- Ⅳ aGVHD, Ⅲ-Ⅳ aGVHD and 180-day TRM showed no significant difference among the patients receiving ABO- identical, minor, major, and bidirectional UCBT （all P〉0.05, respectively）. What＇ s more, none of the patients developed pure red-cell aplasia （PRCA） after UCBT. Group A donor and a group O recipient patients didn＇ t appeared to influence the clinical results when compared with others （all ≥0.05, respectively）. Conclusion Patients receive ABO-incompatible UCBT may not develop PRCA. The presence of ABO-incompatibility did not influence the hematopoietic reconstitution, the incidence of aGVHD and 180-day TRM in this cohort. There is not support for the need to regard ABO-compatibility as an UCB-graft selection criterion.